BE505709A - - Google Patents
Info
- Publication number
- BE505709A BE505709A BE505709DA BE505709A BE 505709 A BE505709 A BE 505709A BE 505709D A BE505709D A BE 505709DA BE 505709 A BE505709 A BE 505709A
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- penicillin
- terramycin
- antibiotic
- salmonella
- Prior art date
Links
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 29
- 230000003115 biocidal effect Effects 0.000 claims description 27
- 229930182555 Penicillin Natural products 0.000 claims description 19
- 229940049954 penicillin Drugs 0.000 claims description 19
- 239000003242 anti bacterial agent Substances 0.000 claims description 18
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 claims description 16
- 229940063650 terramycin Drugs 0.000 claims description 13
- 229940056360 penicillin g Drugs 0.000 claims description 9
- SVDOODSCHVSYEK-IFLJXUKPSA-N (4s,4ar,5s,5ar,6s,12ar)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O SVDOODSCHVSYEK-IFLJXUKPSA-N 0.000 claims description 8
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 claims description 4
- -1 penicillin salt Chemical class 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 244000005700 microbiome Species 0.000 description 19
- 241000607142 Salmonella Species 0.000 description 13
- 229940088710 antibiotic agent Drugs 0.000 description 13
- 230000000694 effects Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 241000589516 Pseudomonas Species 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- IMLJLCJZQLGHJS-JEKSYDDFSA-N (4s,4ar,5s,5ar,6s,12ar)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;dihydrate Chemical compound O.O.C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O IMLJLCJZQLGHJS-JEKSYDDFSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ACAZKHULUUVWCY-JFGNBEQYSA-N (2s,5r,6r)-6-(hexanoylamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound S1C(C)(C)[C@H](C(O)=O)N2C(=O)[C@@H](NC(=O)CCCCC)[C@H]21 ACAZKHULUUVWCY-JFGNBEQYSA-N 0.000 description 1
- ACAZKHULUUVWCY-UHFFFAOYSA-N 6beta-hexanoylamino-penicillanic acid Natural products S1C(C)(C)C(C(O)=O)N2C(=O)C(NC(=O)CCCCC)C21 ACAZKHULUUVWCY-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033971 Paratyphoid fever Diseases 0.000 description 1
- QRLCJUNAKLMRGP-UHFFFAOYSA-N Penicillin F Natural products S1C(C)(C)C(C(O)=O)N2C(=O)C(NC(=O)CC=CCC)C21 QRLCJUNAKLMRGP-UHFFFAOYSA-N 0.000 description 1
- QRLCJUNAKLMRGP-ZTWGYATJSA-N Penicillin F Chemical compound S1C(C)(C)[C@H](C(O)=O)N2C(=O)[C@@H](NC(=O)C/C=C/CC)[C@H]21 QRLCJUNAKLMRGP-ZTWGYATJSA-N 0.000 description 1
- XVASOOUVMJAZNJ-MBNYWOFBSA-N Penicillin K Chemical compound S1C(C)(C)[C@H](C(O)=O)N2C(=O)[C@@H](NC(=O)CCCCCCC)[C@H]21 XVASOOUVMJAZNJ-MBNYWOFBSA-N 0.000 description 1
- 241000228150 Penicillium chrysogenum Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000187419 Streptomyces rimosus Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 239000004247 glycine and its sodium salt Substances 0.000 description 1
- 239000001056 green pigment Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 229940029258 sodium glycinate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- WUWHFEHKUQVYLF-UHFFFAOYSA-M sodium;2-aminoacetate Chemical compound [Na+].NCC([O-])=O WUWHFEHKUQVYLF-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE505709A true BE505709A (enrdf_load_stackoverflow) |
Family
ID=146172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE505709D BE505709A (enrdf_load_stackoverflow) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE505709A (enrdf_load_stackoverflow) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2824877A (en) * | 1956-02-01 | 1958-02-25 | Bristol Lab Inc | Benzyl-penicilloate of tetracycline |
| US2837513A (en) * | 1955-02-03 | 1958-06-03 | Rhone Poulenc Sa | Penicillin salts |
| WO1984004249A3 (fr) * | 1983-05-03 | 1985-03-14 | Ssm Int Chem Co Ltd | Composition a activite pharmaceutique amelioree et utilisation decelle-ci pour des usages veterinaires |
-
0
- BE BE505709D patent/BE505709A/fr unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2837513A (en) * | 1955-02-03 | 1958-06-03 | Rhone Poulenc Sa | Penicillin salts |
| US2824877A (en) * | 1956-02-01 | 1958-02-25 | Bristol Lab Inc | Benzyl-penicilloate of tetracycline |
| WO1984004249A3 (fr) * | 1983-05-03 | 1985-03-14 | Ssm Int Chem Co Ltd | Composition a activite pharmaceutique amelioree et utilisation decelle-ci pour des usages veterinaires |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69930944T2 (de) | Bacillus coagulans-zusammensetzung und deren verwendung | |
| JPH09501702A (ja) | 増強された抗生物質組成物 | |
| EP2437737B1 (fr) | Composition comprenant au moins du trans-cinnamaldehyde et son utilisation dans le traitement des infections bacteriennes plus particulierement dans le traitement des maladies nosocomiales | |
| JP2001526179A (ja) | 金属／チオール殺生剤 | |
| JP2011510045A (ja) | 動物においてグラム陽性バクテリアにより引き起こされる感染症の予防及び処置の為のラクチレート | |
| KR20130064004A (ko) | 기존 세파계 항생제 및 베타 락타마제 저해제로 배합된 내성균주에 기인한 감염증의 치료 및 예방을 위한 복합항생제 | |
| JP6506259B2 (ja) | シュードアルテロモナス（Ｐｓｅｕｄｏａｌｔｅｒｏｍｏｎａｓ）属由来の単離された細菌の使用、シクロリポペプチド、及びその使用 | |
| US20060073156A1 (en) | Fosfomycin and n-acetylcysteine for the treatment of biofilms caused by escheric ia coli and other pathogens of the urinary tract | |
| BE505709A (enrdf_load_stackoverflow) | ||
| KR102203849B1 (ko) | 동물용 복합 항생제 조성물 | |
| FR2472389A1 (fr) | Compositions antibiotiques contenant un macrolide et un aminoheteroside | |
| FR2974012A1 (fr) | Utilisation de calixarenes dans le traitement des infections bacteriennes | |
| KR101971572B1 (ko) | 신규한 살모넬라 엔테리티디스 특이 박테리오파지 및 이를 포함하는 항균 조성물 | |
| FR2521006A1 (fr) | Nouveau medicament compose utile notamment pour le traitement des maladies infectieuses | |
| FR3052065B1 (fr) | Combinaison de cineol et d'amoxicilline pour une utilisation dans le traitement d'une infection bacterienne | |
| KR102430080B1 (ko) | 메틸 갈레이트 및 틸로신을 포함하는 항균용 조성물 | |
| KR100512098B1 (ko) | 레불린산 및 그의 유도체를 함유한 항생제, 화장품 및 식품 | |
| BE825937A (fr) | Compositions antibacteriennes comprenant un compose de cephalosporine et un compose de penicilline | |
| JPS641441B2 (enrdf_load_stackoverflow) | ||
| JPH0225890B2 (enrdf_load_stackoverflow) | ||
| FR3052066B1 (fr) | Formulation pharmaceutique de cineol et d'amoxicilline | |
| CN119770530A (zh) | 一株可改善口腔健康的海洋源植物乳植杆菌hj-s2及应用 | |
| Thomas | The role of Fusarium solani in the biodeterioration of a pharmaceutical product | |
| BE502262A (enrdf_load_stackoverflow) | ||
| JP2001524523A (ja) | 出血性大腸菌感染治療剤の製造のためのビコザマイシンの使用 |